Grafting of these cells under the renal capsule [24] or injection of these cells into the spleen or the peritoneal cavity [36] might contribute to the treatment of AHL and the rejuvenation of the recipients to decrease IL-1R2+ CD4+ T cells and Tregs. The gene discussed is CD4; the disease is acute hemorrhagic leukoencephalitis.